Long term hold for me with mnkd investment as I beleive the company will succeed phenomenally. I'm disappointed with the dilution and FDA's political agenda as all investors are.

As has been stated, getting the trials fully enrolled and started by the beginning of Q2 is extremely important from a timing standpoint. I don't beleive there will be any problems with trial data, in fact, I think it will bear out that Afrezza is even more valuable a tool to treat diabetes than data to date has shown. I'm looking forward to approval in Q4 2013. GL!